Current developments in the use of transcatheter aortic valve implantation in high-risk patients Vijaya K Pera,1 Sanjeevan Pasupati2 1Cardiovascular Division, University of Minnesota, Minneapolis, MN, USA; 2Department of Cardiology, Waikato Hospital, Hamilton, New Zealand Abstract: Transcatheter aortic valve implantation (TAVI) has revolutionized the landscape of interventional cardiology. Since its introduction in 2002 by Cribier, this novel technology has developed remarkably over time, with new generations of devices, a reduction in profile sizes, and new access routes, allowing for safer and more efficacious procedures. Innovation brings new solutions as well as new challenges. The initial promising results have not only created high expectations but also a need to address the shortcomings of this procedure. Improved understanding of the potential complications associated with TAVI might help improve outcomes and broaden the application of this rapidly evolving, innovative therapy. This paper summarizes the current evidence, discusses the limitations of current TAVI technology, and highlights future perspectives. Keywords: aortic stenosis, transcatheter aortic valve implantation